Boca Raton, Florida, March 11, 2026—Richard H. Mann, DPM, Chief Scientific Officer of Realm Labs, makers of the NeuRemedy® line of benfotiamine products, announced the publication of a peer-reviewed case series examining a nutritional approach to cognitive symptoms associated with Long COVID.
The article, titled “Improvement in Long COVID Brain Fog After Benfotiamine and Methylcobalamin Supplementation: Case Report Series and Review of the Literature,” appears in the Medical Research Archives, the journal of the European Society of Medicine (Volume 14, Issue 2, February 2026).
The publication describes three patients with persistent cognitive symptoms following COVID-19 infection who received oral supplementation with benfotiamine (a derivative of vitamin B1) and methylcobalamin (vitamin B12). In these cases, patients reported improvements in cognitive clarity within approximately one month.
“These findings are intended to contribute to the growing body of research on Long COVID neurological symptoms,” said Dr. Mann. “Decreased mitochondrial energy production is likely involved with Long COVID symptomatology—including peripheral neuropathy, fatigue, and brain fog. Benfotiamine has a compelling theoretical basis for improving mitochondrial energy production in Long COVID, grounded in its role in correcting functional thiamine insufficiency, restoring enzyme activity, and reducing oxidative mitochondrial stress—all of which are documented features of Long COVID pathology. Improvements reported in these three cases are encouraging; however, the case series is observational and should be considered hypothesis-generating. Further controlled studies are needed to better understand these findings.”
Access the Article:
https://esmed.org/MRA/mra/article/view/7250
———
Media Contact:
Richard H. Mann, DPM
realmlabs123@gmail.com
561-549-9099
